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Objective: The sentinel node concept is of great value in the treatment of various malignancies. In this study we
investigated whether the application of the sentinel node procedure is feasible in esophageal adenocarcinoma and
whether it can tailor surgical treatment of the individual patient.
Methods: In 40 patients with an adenocarcinoma of the distal esophagus or gastroesophageal junction, blue dye
was injected around the tumor intraoperatively. Sentinel nodes (blue-stained) and nonsentinel nodes were iden-
tified and dissected during transhiatal esophagectomy. In sentinel nodes negative for tumor cells on routine he-
matoxylin-eosin examination, multilevel sectioning and immunohistochemical staining were performed to search
for micrometastases.
Results: The sentinel node procedure was technically successful in 39 of 40 patients (98%). The median number
of sentinel nodes identified was 4. Sentinel nodes were present in more than 1 nodal station in 8 patients (21%). In
6 patients in whom the sentinel node was negative for metastasis, nonsentinel nodes were positive for tumor cells
(false-negative rate 6/39 ¼ 15%). Micrometastases and isolated tumor cells were detected in 7 of 19 patients
(37%) with sentinel nodes, but this finding did not affect the false-negative rate.
Conclusion: Detection of sentinel nodes is technically feasible during esophagectomy for cancer. However,
given the relatively high false-negative rate of 15% and the high frequency of sentinel nodes in more than 1 nodal
station, the clinical relevance of the sentinel node concept (through application of the blue dye technique) in the
current treatment of patients with an adenocarcinoma of the distal esophagus or gastroesophageal junction seems
limited.
General Thoracic Surgery Grotenhuis et alMost esophageal adenocarcinomas arise from the lower
esophagus and the gastroesophageal junction (GEJ).1,2
Prognosis after diagnosis is still poor, and overall 5-year
survivals rarely exceed 20%. One of the strongest predictors
of long-term survival after radical (R0) esophagectomy
is the presence of lymph node metastasis.3-5 However,
extended lymphadenectomy for the removal of all locore-
gional nodes can be at the cost of increased perioperative
morbidity.6,7 Therefore, this approach should ideally be
restricted to those patients who are most likely to benefit.
A tailored surgical treatment for the individual patient
may be applicable with the help of the sentinel node concept.
It states that the first lymph nodes (or a single lymph node)
that receive the most direct lymph drainage from the primary
tumor have the greatest potential to harbor metastatic disease
when present.8,9 On this basis, examination of the sentinel
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Thus, applying the sentinel node concept to esophageal
cancer may have 2 important clinical implications. First, it
may allow for the selection of patients who are not likely
to benefit from an extended lymphadenectomy. If the senti-
nel node is not involved, then patients could be spared more
extensive surgery by tailoring the extent of lymphadenec-
tomy. Second, it may affect the process of pathologic exam-
ination of the resected lymph nodes. Immunohistochemical
detection of micrometastases and isolated tumor cells has
been reported10-12 and was found to be clinically relevant
in one study.12
The sentinel node concept has not been studied exten-
sively in esophageal cancer. We hypothesize that identifica-
tion of the sentinel node(s) in esophageal adenocarcinoma
can be achieved with a low false-negative rate and a high
accuracy. In this study, we determined the feasibility of
application of the sentinel node procedure in adenocarci-
nomas of the distal esophagus and GEJ (with the false-
negative rate as the primary outcome parameter) and evalu-
ated its value in the clinical setting.
PATIENTS AND METHODS
Patients
During a 14-month period (May 2000 to June 2001), 101 patients under-
went an esophageal resection and reconstruction for cancer of the distalrgery c September 2009
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H&E ¼ hematoxylin-eosin
GEJ ¼ gastroesophageal junction
esophagus or GEJ at the Erasmus Medical Center. These patients were eval-
uated for inclusion in the study on the basis of the following criteria: histo-
logically proven adenocarcinoma of the distal esophagus or GEJ
preoperatively (Siewert type I or II, respectively) and no application of neo-
adjuvant chemotherapy or radiotherapy. Induction chemotherapy or radio-
therapy was given in patients with a cT4-tumor without distant metastases
or in patients with involvement of celiac trunk lymph nodes (M1a), who
were not considered eligible for primary surgical therapy. Chemotherapy
or radiotherapy was performed before surgery in 30 patients; histologic
examination confirmed a squamous cell carcinoma in 20 patients; surgery
for high-grade dysplasia was performed in 2 patients; and a double tumor
of the esophagus led to exclusion in 1 patient. Eight patients did not partic-
ipate in the study for logistic reasons. Consequently, 40 patients were
included in this study, and the sentinel node procedure was performed as
described below. Informed consent was obtained from the patients before
operation. The Medical Ethics Committee of the Erasmus Medical Center
approved the study.
Sentinel Node Mapping
Mapping of the sentinel nodes was carried out in vivo after opening
the hiatus of the diaphragm and mobilizing the GEJ under direct vision.
Minimal dissection was performed to maintain intact lymph channels. At
3 different sites in the vicinity of the tumor, 1 to 2 mL Patent Blue V
(Guerbet-Laboratories, Issy les Moulineaux, France) was injected into the
submucosal layer.Within the next 5 minutes, the sentinel node(s) were iden-
tified by following the blue-stained lymphatic vessels. These nodes were
tagged with a suture. Once the resection specimen was taken out, the senti-
nel nodes were harvested ex vivo and sent as a separate specimen to the
Department of Pathology. The remaining non–blue-stained lymph nodes
present in the resection specimen (nonsentinel nodes) were identified by
the pathologist and categorized according to the location as paraesophageal,
perigastric, or celiac trunk nodes.
Surgery
All patients underwent a transhiatal esophagectomy. The primary tumor
and its adjacent lymph nodes were dissected under direct vision through the
widened hiatus of the diaphragm up to the level of the inferior pulmonary
vein. Subsequently, a gastric tube was created. The left gastric artery was
transected at its origin, with en bloc resection of celiac trunk lymph nodes.
After mobilization and transection of the cervical esophagus, the intratho-
racic esophagus was mobilized bluntly from the neck to the abdomen
with a vein stripper. Esophagogastrostomywas performed in the neck, with-
out a formal cervical lymphadenectomy.
Pathology
Pathologic evaluation of all lymph nodes consisted of conventional
hematoxylin-eosin (H&E) staining. If no tumor cells were identified in
the sentinel node(s), multilevel serial sectioning was performed. These
lymph nodes were cut at 10 levels of approximately 100 mm (dependent
on lymph nodes’ size). Subsequently, sections were cut with a thickness
of 4 mm and examined for tumor cells with H&E staining and immunohis-
tochemistry to reveal micrometastases (metastatic lesions> 0.2 mm in
dimension but < 2.0 mm) and isolated tumor cells (metastatic lesions
< 0.2 mm in dimension).13,14 The mouse-monoclonal antibody CAM 5.2
(NCL5D3, Novo Castra, Wetzlar, Germany), which is specific for intracel-
lular cytokeratin-8 and 18, was used for this experiment.15The Journal of Thoracic andStatistics
To allow for intrapatient dependencies between outcomes of the investi-
gated lymph nodes, the method of generalized estimating equations was
used (SAS PROC GENMOD, SAS Institute Inc, Cary, NC).
RESULTS
The sentinel node procedure was attempted in 40 patients
who underwent a transhiatal esophagectomy. Patients’ char-
acteristics are described in Table 1. In 3 patients a large
tumor covered both the distal esophagus and the GEJ
(type I/II), and no proper distinction between a type I or II
tumor could be made.
The sentinel node procedure was successful in identifying
1 or more sentinel nodes in 39 of 40 patients (98%). Tech-
nical failure occurred in 1 patient: The blue specimen that
was presumed to be the sentinel node did not contain any
lymphatic tissue when examined by the pathologist. Thus,
the data of this patient were excluded from further analysis.
A total of 424 lymph nodes were resected, comprising
both sentinel nodes (N ¼ 143) and nonsentinel nodes
(N ¼ 281). The median number of sentinel nodes identified
per patient was 4 (range 1–9), whereas the number of non-
sentinel nodes accounted for a median of 7 nodes per patient
(range 1–22). The location of the identified sentinel nodes in
relation to tumor site is shown in Table 2. The percentage of
paraesophageal sentinel nodes was significantly higher in
patients with a Siewert type I tumor than in patients with
a Siewert type II tumor: 64% (45/70) versus 11% (7/64)
(P< .001). On the other hand, for sentinel nodes situated
in the perigastric area, these percentages were 29%
(20/70) for Siewert type I tumors and 77% (49/64) for
Siewert type II tumors (P ¼ .002). In 1 patient with a type
I tumor, no sentinel node could be identified during the
abdominal phase of the operation; however, 2 blue nodes
(5%) were detected coincidentally in the cervical region,
implicating an upward lymphatic drainage. Eight patients
(21%) had sentinel nodes present in more than 1 nodal
TABLE 1. Patients’ characteristics
Gender
Male 30 (75%)
Female 10 (25%)
Agea 62 y (range 41–80 y)
pT-stadium
pT1 9 (23%)
pT2 5 (13%)
pT3 26 (65%)
Barrett’s metaplasia
Yes 24 (60%)
No 16 (40%)
Tumor location
Siewert I 20 (50%)
Siewert II 17 (43%)
Siewert I/II 3 (8%)
aAge is given as median.Cardiovascular Surgery c Volume 138, Number 3 609
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was applied successfully, the sentinel node was located
adjacent to the tumor in 30 patients (77%).
Of the total number of 424 lymph nodes examined by
means of standard H&E staining, the sentinel nodes were
more likely to contain tumor cells than the nonsentinel no-
des; 40 of 143 (28%) sentinel nodes were positive versus
52 of 281 (19%) nonsentinel nodes (P ¼ 0.046, Table 3).
In 20 of 39 patients (51%), the sentinel node contained
tumor metastasis diagnosed on routine H&E examination.
In 8 patients (21%), only the sentinel node accounted for
the N1-status of the patient; in 12 patients (31%), there
were also nonsentinel nodes in which a metastasis was
found. In the remaining 19 patients (49%), the sentinel
node was scored negative for tumor cells (Table 4). How-
ever, in 6 of these 19 patients, metastases were found in
the nonsentinel nodes, which involved 1 patient with
a pT1 tumor, 1 patient with a pT2 tumor, and 4 patients
with a pT3 tumor. These data correspond with a false-
negative rate of 15% (6/39 patients), a negative predictive
value of 68% (13/19), an accuracy of 85% (33/39), a sensi-
tivity of 77% (20/26), and a specificity of 100% (13/13) of
the sentinel node procedure in our study (Table 5).
In patients in whom no metastasis was detected in the
sentinel node by H&E staining (N ¼ 19), multilevel serial
sectioning and immunohistochemical staining with CAM
5.2 were performed (in the sentinel nodes only). In 1 patient
this revealed a macrometastasis that was not present in the
conventional H&E section; a micrometastasis was identified
in 1 patient and isolated tumor cells were identified in
5 patients, resulting in upstaging of the histologic diagnosis
in 7 patients (Table 4). These results did not affect the false-
negative rate of 15% (Table 5) because patients’ lymph
node status was not revised in any of the 6 patients in
whom only nonsentinel nodes were scored positive (false-
negatives in this study).
DISCUSSION
In this study we investigated the application of the senti-
nel node procedure in the surgical treatment of patients with
esophageal adenocarcinoma. The sentinel node procedure
was technically successful in 39 of 40 patients (98%). The
median number of sentinel nodes identified per patient was
TABLE 2. Relation between location of the sentinel node and tumor
site
Sentinel node location
Tumor site Cervical Paraesophageal Perigastric
Celiac
trunk Total
Siewert I (N ¼ 20) 2 45 20 3 70
Siewert II (N ¼ 16) 0 7 49 8 64
Siewert I/II (N ¼ 3) 0 2 7 0 9
Total (N ¼ 39) 2 54 76 11 143610 The Journal of Thoracic and Cardiovascular Su4 (range 1–9), and these sentinel nodes were present in
more than 1 nodal station in 8 patients (21%). In 6 patients
in whom the sentinel node was negative for metastasis,
nonsentinel nodes were positive for tumor cells (false-
negative rate 6/39 ¼ 15%). Micrometastases and isolated
tumor cells were detected in 7 of 19 patients (37%) with
negative sentinel nodes, but this finding did not affect the
false-negative rate.
The term ‘‘sentinel node’’ was introduced in 1960
by Gould and colleagues16 in their study to detect lymphatic
metastases in parotid carcinoma. The procedure was
further refined in patients with melanoma8 and breast can-
cer.9 Especially in breast cancer, the procedure has become
a widely accepted element in the routine surgical manage-
ment.17 In gastrointestinal tumors, the use of this procedure
is still under investigation. During the last 10 years, a consid-
erable number of clinical trials evaluating the feasibility and
accuracy of the sentinel node procedure primarily in gastric
and colorectal carcinoma have been published. With regard
to gastric cancer, a complex lymphatic drainage is consid-
ered to result in high frequencies of skip metastases
(15%–20%).18,19 These trials show high false-negative
rates (ranging from 0%–39%).20,21 Thus, a tailored surgical
approach with regard to lymphadenectomy based on this
procedure in patients with gastric cancer is not justified. In
colorectal cancer, all regional lymph nodes are routinely
removed with the resected bowel segment. Thus, minimiz-
ing surgical resection is not a major goal of the sentinel
TABLE 3. Total number of lymph nodes derived from esophagectomy
specimens of 39 patients: Relation between sentinel and nonsentinel
nodes and tumor involvement as judged by hematoxylin-eosin
examination
Sentinel node Nonsentinel node Total
Positive (Nþ) 40 52 92
Negative (N) 103 229 332
Total 143 281 424
TABLE 4. Nodal status (tumor positive [þ] and negative [] of 39
patients after esophagectomy for cancer: Relation between sentinel
and nonsentinel nodes
Before multilevel sectioning and immunohistochemistry
Nonsentinel nodeþ Nonsentinel node Total
Sentinel nodeþ 12 8 20
Sentinel node 6 13 19
Total 18 21 39
After multilevel sectioning and immunohistochemistry
Nonsentinel Nodeþ Nonsentinel node Total
Sentinel nodeþ 12 15 27
Sentinel node 6 6 12
Total 18 21 39rgery c September 2009
Grotenhuis et al General Thoracic SurgeryTABLE 5. Definitions of diagnostic test parameters and corresponding values in 39 patients (before and after multilevel sectioning and
immunohistochemistry)
Definition Value before IHC Value after IHC
False-negative rate No. of false-negative SNs/No. of patients with an identified SN 6/39 ¼ 15% 6/39 ¼ 15%
Negative predictive value No. of patients with true-negative node (SNþNSN)/No. of patients with true-negative
nodeþpatients with false-negative SN
13/19 ¼ 68% 6/12 ¼ 50%
Accuracy No. of patients with positive SNþNo. of patients with true-negative SN/No. of patients
with an identified SN
33/39 ¼ 85% 33/39 ¼ 85%
Sensitivity No. of patients with true-positive SN/No. of patients with true-positive SNþpatients
with false-negative SN
20/26 ¼ 77% 27/33 ¼ 82%
Specificity No. of patients with true-negative SN/No. of patients with true-negative SNþpatients
with false-positive SN
13/13 ¼ 100% 6/6 ¼ 100%
SN, Sentinel node; NSN, nonsentinel node.G
T
Snode procedure in patients with colorectal cancer. Instead,
improved prognostication is the main target.22
The lymphatic drainage of the esophagus is complex
with abundant lymph-capillary networks, especially in the
submucosa.23,24 This results in a longitudinal lymphatic
drainage, which is presumed to be the reason for the phe-
nomenon of skipping lymph node metastases in esophageal
cancer.25 Skip metastases are present when there is no tumor
cell spread from the primary tumor into the adjacent peritu-
moral lymph nodes in the presence of positive distant nodes.
For esophageal adenocarcinomas, skip metastases have been
reported in 0% to 35% of patients.7,25,26 Because all
patients in our study underwent transhiatal esophagectomy,
a thorough analysis of the lymphatic spread in the upper part
of the chest was not possible. In patients with a Siewert type
I tumor, the sentinel node was mainly located along the
esophagus, whereas in most patients with a Siewert type II
tumor the gastric nodal station contained the sentinel node.
These results correlate with the patterns of lymphatic spread
for these tumor entities as described in the literature.27
Furthermore, 2 sentinel nodes were found coincidentally
in the cervical region (5%), representing the complex and
unpredictable lymphatic spread of esophageal cancer cells.
We found a false-negative rate of 15%, which is higher in
comparison with other malignancies. For example, false-
negative rates between 0% and 5% for breast cancer have
been reported and are considered to be acceptable world-
wide.17,28 Furthermore, sentinel nodes were identified in
more than 1 nodal station in 8 patients (21%), whereas ide-
ally the sentinel node presents as a solitary lymph node to
enhance the usefulness of the sentinel node concept in clin-
ical practice. In our study, a median of 4 sentinel nodes per
patient were detected, indicating that half of the patients had
4 or more (up to 9) blue-stained nodes. These sentinel nodes
were harvested during a transhiatal approach with a limited
lymphadenectomy. One could hypothesize that if a transtho-
racic esophagectomy with a 2-field lymphadenectomy had-
been performed, the false-negative rate may have been
lower (blue-stained lymph nodes may have been present in
the upper mediastinum) as well as higher (if mediastinalThe Journal of Thoracic andnonsentinel nodes positive for tumor could have been
detected). One study investigating the use of the sentinel
node procedure in esophageal adenocarcinomas showed
that when extended lymphadenectomy was performed, the
lower paraesophageal and left gastric artery nodal stations
were the most common sites of sentinel node identifica-
tion.29 In contrast, the upper mediastinal nodal basins ac-
counted for only 3% (4/131) of the sentinel node stations.
Therefore, we do not believe that the applied transhiatal
approach with a limited lymphadenectomy is a major draw-
back in the current study.
Two other studies have been published thus far that inves-
tigated the sentinel node procedure in esophageal adenocar-
cinomas.29,30 In the first study, Lamb and colleagues29
identified at least 1 sentinel node bymeans of peritumoral in-
jection (before the operation) of radioactive nanocolloid in
all 57 patients with a type I or II tumor (no blue dye was
used). A false-negative rate of 5% was reported. Hence,
one could argue that in our study the use of blue dye only
is a technical shortcoming. However, this approach has
been described before.20,21 Nonetheless, blue dye and radio-
colloid are considered to act as complementary techniques in
breast cancer.28
The second study demonstrated that sentinel node detec-
tion was feasible in 17 of 20 patients using a combination
of blue dye and radiocolloid injection (N¼ 10) and radiocol-
loid injection only (N¼ 10).30 No data were shown to clarify
whether the use of blue dye and radiocolloid are comple-
mentary. Lymph node status was correctly predicted in all
type I tumors and in 75% of type II and III tumors. Further-
more, advanced tumors had a higher false-negative rate, and
therefore it was concluded that the sentinel node procedure
was only applicable in patients with early (pT1-2) cancer.
However, in our study both early and advanced tumors
belonged to the group of false-negatives (1 T1 tumor, 1 T2
tumor, and 4 T3 tumors).
Overall, the use of blue dye only without radiocolloid
injection as a complementary technique may be a potential
drawback in this study. Nevertheless, in our opinion, the
2 above-mentioned studies together with our present findingsCardiovascular Surgery c Volume 138, Number 3 611
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clinical decision making in patients with an adenocarcinoma
of the distal esophagus or GEJ at the ErasmusMedical Center.
CONCLUSIONS
The sentinel node procedure is technically feasible during
transhiatal esophagectomy for esophageal cancer. However,
given the high false-negative rate and the high frequency of
sentinel nodes in more than 1 nodal station, the clinical rel-
evance of the sentinel node concept by application of the
blue dye technique only in the current treatment of patients
with an adenocarcinoma of the distal esophagus or GEJ
seems limited. More studies are needed that should focus
on using the blue-dye technique in combination with radio-
colloid injection and extended lymphadenectomy.
We thankMiriam de Jong, MD, for the preparation of this study.
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